跳至主要内容
临床试验/2024-517002-28-01
2024-517002-28-01招募中1 期

Phase I-Ib clinical trial of safety and immunobiology of prophylactic infusion of lymphocytes and NK cells after Allo-HCT.

Red De Apoyo A La Investigacion Clinica En Hematologia Y Hemoterapia S.L., Vall D Hebron Institute Of Oncology1 个研究点 分布在 1 个国家目标入组 8 人开始时间: 2025年6月27日最近更新:
适应症

试验速览

阶段
1 期
状态
招募中
发起方
入组人数
8
试验地点
1

研究概览

简要总结

暂无简介。

入排标准

年龄范围
18 years 至 65+ years(18-64 Years, 65+ Years)
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究者

发起方
Red De Apoyo A La Investigacion Clinica En Hematologia Y Hemoterapia S.L., Vall D Hebron Institute Of Oncology
申办方类型
Pharmaceutical company, Laboratory/Research/Testing facility
责任方
Principal Investigator
主要研究者

scientific information

Scientific

Red De Apoyo A La Investigacion Clinica En Hematologia Y Hemoterapia S.L.

研究点 (1)

Loading locations...

相似试验

进行中(未招募)
1 期
Safety study of DIPG treatment with autologous dendritic cells pulsed with lysated allegenic tumor linesDiffuse intrinsic pontine glioma (DIPG)MedDRA version: 19.0Level: PTClassification code 10006143Term: Brain stem gliomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2015-003362-84-ESFundació Sant Joan de Déu
已完成
不适用
Phase I clinical trial to assess safety and immunogenicity of an MVA-based influenza H5 vaccine in healthy adultsflu10047438Influenza
NL-OMON38408Erasmus MC, Universitair Medisch Centrum Rotterdam27
已完成
不适用
A safety and immunogenicity phase 1 trial with an adjuvated TB subunit vaccine (Ag85B - ESAT-6 + IC31) administered in PPD positive volunteers at 0 and 2 monthsPrevention10028440Tuberculosis
NL-OMON30684Statens Serum Institut20
撤回
1/2 期
A Phase 1/Phase 2 Trial to Evaluate Safety, Immunogenicity and PSA Response of VTP-850 Prostate Cancer Immunotherapeutic in Men with Biochemical Recurrence after Definitive Local Therapy for Prostate CancerProstate Cancer
2023-504066-39-00Vaccitech PLC22
进行中(未招募)
1 期
Safety and immunogenicity of RNA-based vaccines against SARS-CoV-2 variants in healthy participantsProtection against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2).MedDRA version: 23.0Level: PTClassification code 10051905Term: Coronavirus infectionSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 23.0Level: HLTClassification code 10084510Term: Coronavirus infectionsSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 23.1Level: LLTClassification code 10084529Term: 2019 novel coronavirus infectionSystem Organ Class: 10021881 - Infections and infestations
EUCTR2021-003458-22-DEBioNTech SE1,470